GSK raises fists in $2.6B hostile bid for Human Genome Sciences

The gloves are off. GlaxoSmithKline ($GSK) has mounted a hostile offer for its long-time partner Human Genome Sciences ($HGSI), whose board shot down GSK buyout bid last month but invited the London-b…
Read the full story: News